← Back to all signals
RESEARCH PAPER ANALYSIS

Delirium and in-hospital falls in older adults: factors associated with fall occurrence and number of falls.

In a retrospective cohort of 12,866 hospitalizations of adults ≥65, delirium was independently associated with higher odds and counts of in-hospital falls (OR 1.51, IRR 1.47), with Parkinson's disease, male sex, and antipsychotic exposure also linked to falls and baseline functional status…

PMID42008203
JournalEuropean geriatric medicine
Publication Date2026-04-20
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

In a retrospective cohort of 12,866 hospitalizations of adults ≥65, delirium was independently associated with higher odds and counts of in-hospital falls (OR 1.51, IRR 1.47), with Parkinson's disease, male sex, and antipsychotic exposure also linked to falls and baseline functional status…

WHY IT MATTERS

Research significance

Low direct value for Parkinson's therapeutic discovery, but clinically relevant for PD care because preventing or managing delirium in hospitalized PD patients may reduce fall risk and related morbidity, suggesting targets for care-pathway interventions rather than molecular therapeutics.

ABSTRACT

Source abstract

PURPOSE: To examine the association between delirium and in-hospital falls in older adults, including fall occurrence and number of falls, and to assess whether fall-related factors differ according to delirium status. METHODS: We conducted a retrospective cohort study of patients aged ≥ 65 years hospitalized in acute geriatric units between 2022 and 2024. Delirium was identified using ICD-10 codes, Confusion Assessment Method (CAM) documentation, and physician-entered diagnoses. Fall occurrence (≥ 1 fall) was analysed using multivariable logistic regression and number of falls using negative binomial regression. Analyses were stratified according to delirium status. RESULTS: Among 12,866 hospitalizations, 1751 patients (13.6%) experienced at least one in-hospital fall. Delirium occurred in 2889 patients (22.5%) and was independently associated with fall occurrence (OR 1.51, 95% CI 1.32-1.72). Male sex (OR 1.56, 95% CI 1.39-1.74), Parkinson's disease (OR 1.52, 95% CI 1.23-1.89), and antipsychotic exposure were also associated with falls. Baseline functional status showed a significant interaction with delirium status (p = 0.0002): higher functional independence was associated with lower fall risk in patients without delirium (OR per 10-point FIM increase 0.91, 95% CI 0.89-0.94), but not in those with delirium (OR 0.99, 95% CI 0.95-1.03). Delirium was also independently associated with a higher fall count (IRR 1.47, 95% CI 1.31-1.66). CONCLUSION: Delirium is independently associated with both the occurrence and number of in-hospital falls. Once delirium develops, fall risk appears to reflect a state of acute neurocognitive instability in which baseline functional status loses much of its discriminative value for risk stratification.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic